Zelluna Immunotherapy and Glycostem Therapeutics have partnered to develop allogeneic TCR-NK therapies.
Danish Novo Nordisk A/S has secured access to Dicerna Inc’s GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets.
The EU has made poor progress combatting antimicrobial resistance, a report from the European Court of Auditors (ECA) warns. Innovators need to be supported, urges the BEAM Alliance.
Researchers at French-US allogeneic CAR-T cell developer Cellectis SA have designed an engineered CAR-T cell that secretes IL-12 upon contact with tumour cells.
Magenta Therapeutics has exercised the option to licence Heidelberg Pharma AG’s anti-CD45-Antibody Targeted Amanitin Conjugate (ATAC).
Swiss-German biotech Vaximm is teaming up with Tokyo-based AI specialist NEC to advance personalised neoantigen cancer vaccines.
Expedeon has sold its immunology and proteomics business activities to global life sciences company Abcam. Abcam is paying €120m in cash for the business.
Autoimmunity specialist SciRhom GmbH has kicked of a first-in-class antibody development programme targeting iRhom2.
A drug combo breaking antibiotic resistance of Gram-negative priority pathogens has been selected under the ENABLE programme of the Innovative Medicines Initiative (IMI).
Bergen Bio ASA’s Axl kinase blocker bemcentinib in combination with MSD’s pembrolizumab has met the primary endpoint in a Phase II study in patients with non small cell lung cancer (NSCLC).